Haemonetics has announced that for the first time, patients have been treated with the company’s Vascade MVP Venous Vascular Closure system in Germany. This marks the first use of the Vascade system portfolio, widely used in U.S. hospitals, in a European country.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on HAE:
- Haemonetics price target raised to $114 from $111 at Barrington
- Haemonetics raises FY24 adjusted EPS view to $3.60-$3.90 from $3.45-$3.75
- Haemonetics 1st Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website
- Haemonetics reports Q1 adjusted EPS $1.05, consensus 73c
- HAE Earnings this Week: How Will it Perform?